Louise Uoselis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Louise Uoselis has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Michael Lazarou
Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Melbourne, Australia
5 shared publications - Marvin Skulsuppaisarn
Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia
4 shared publications - Thanh Ngoc Nguyen
Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, USA
4 shared publications - Runa S. J. Lindblom
Walter and Eliza Hall Institute of Medical Research
3 shared publications - Aleksandra Filipovska
The Kids Research Institute Australia, Northern Entrance, Perth Children’s Hospital, 15 Hospital Avenue, Nedlands, Western Australia 6009, Australia
2 shared publications - Danielle L. Rudler
School of Human Sciences Perth WA 6009 The University of Western Australia
2 shared publications
Latest Publications
- Open Access
- 10 March 2025
- Published by Taylor & Francis in Autophagy
- Vol. 21 (7) , 1456-1472
Cancer-associated mutations in autophagy-related proteins analyzed in yeast and human cells
Macroautophagy/autophagy is a conserved process among eukaryotes and is essential to maintain cell homeostasis; the dysregulation of autophagy has been linked with multiple human diseases, including cancer. However, not many studies have focused on the cancer-related mutations in ATG (autophagy related) proteins, which are likely to affect the protein function, influence autophagy activity and further contribute to the progression of the disease. In this study, we focused on the four ATG4 isoforms, which have a higher mutation frequency compared with the other core ATG proteins (i.e. those involved in autophagosome formation). We first studied the mutations in conserved residues and characterized one cancer-associated mutation that significantly impairs protein function and autophagy activity. Extending the study, we determined a region around the mutant residue to be essential for protein function, which had yet to be examined in previous studies. In addition, we created a yeast system expressing the human ATG4B protein to study mutations in the residues that are not conserved from human to yeast. Using this yeast model, we identified six cancer-associated mutations affecting autophagy. The effects of these mutations were further tested in mammalian cells using a quadruple ATG4 gene knockout cell line. Our study proves the principle of using human disease-associated mutations to study Atg proteins in yeast and generates a yeast tool that is helpful for a rapid screen of mutations to determine the autophagy phenotype, providing a new perspective in studying autophagy and its relation with cancer.
- 10 March 2025
- Published by Taylor & Francis in Autophagy
- Vol. 21 (7) , 1456-1472
Open AccessCancer-associated mutations in autophagy-related proteins analyzed in yeast and human cells
Macroautophagy/autophagy is a conserved process among eukaryotes and is essential to maintain cell homeostasis; the dysregulation of autophagy has been linked with multiple human diseases, including cancer. However, not many studies have focused on the cancer-related mutations in ATG (autophagy related) proteins, which are likely to affect the protein function, influence autophagy activity and further contribute to the progression of the disease. In this study, we focused on the four ATG4 isoforms, which have a higher mutation frequency compared with the other core ATG proteins (i.e. those involved in autophagosome formation). We first studied the mutations in conserved residues and characterized one cancer-associated mutation that significantly impairs protein function and autophagy activity. Extending the study, we determined a region around the mutant residue to be essential for protein function, which had yet to be examined in previous studies. In addition, we created a yeast system expressing the human ATG4B protein to study mutations in the residues that are not conserved from human to yeast. Using this yeast model, we identified six cancer-associated mutations affecting autophagy. The effects of these mutations were further tested in mammalian cells using a quadruple ATG4 gene knockout cell line. Our study proves the principle of using human disease-associated mutations to study Atg proteins in yeast and generates a yeast tool that is helpful for a rapid screen of mutations to determine the autophagy phenotype, providing a new perspective in studying autophagy and its relation with cancer.
- Open Access
Presynapses are mitophagy pit stops that prevent axon degeneration
Defects in neuronal mitophagy have been linked to neurodegenerative diseases including Parkinson’s disease. However, despite the importance of mitophagy in neuronal homeostasis, the mechanistic basis for neurodegeneration when mitophagy is defective is unclear. Here, using human neurons, we discover that presynapses are mitophagy pit stops for damaged axonal mitochondria. We show that while mitochondrial damage and PINK1/Parkin activation events are distributed throughout axons, mitophagy initiation and autophagosome formation are restricted to presynapses, which we show contain the machineries required for mitophagy. Being the primary sites of axonal mitophagy, presynapses were vulnerable when PINK1/Parkin mitophagy was defective. We observed local cytochrome c release within presynapses from an accumulation of damaged mitochondria. This resulted in downstream degradative caspase activation, defining a mechanism for neurodegeneration. Pharmacological rescue of axon degeneration was achieved through synthetic upregulation of receptor mediated mitophagy with the clinically approved compound Roxadustat, revealing a potential therapeutic avenue for disease.
Open AccessPresynapses are mitophagy pit stops that prevent axon degeneration
Defects in neuronal mitophagy have been linked to neurodegenerative diseases including Parkinson’s disease. However, despite the importance of mitophagy in neuronal homeostasis, the mechanistic basis for neurodegeneration when mitophagy is defective is unclear. Here, using human neurons, we discover that presynapses are mitophagy pit stops for damaged axonal mitochondria. We show that while mitochondrial damage and PINK1/Parkin activation events are distributed throughout axons, mitophagy initiation and autophagosome formation are restricted to presynapses, which we show contain the machineries required for mitophagy. Being the primary sites of axonal mitophagy, presynapses were vulnerable when PINK1/Parkin mitophagy was defective. We observed local cytochrome c release within presynapses from an accumulation of damaged mitochondria. This resulted in downstream degradative caspase activation, defining a mechanism for neurodegeneration. Pharmacological rescue of axon degeneration was achieved through synthetic upregulation of receptor mediated mitophagy with the clinically approved compound Roxadustat, revealing a potential therapeutic avenue for disease.
- Open Access
- 22 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (38) , eadh8228
Temporal landscape of mitochondrial proteostasis governed by the UPR mt
Breakdown of mitochondrial proteostasis activates quality control pathways including the mitochondrial unfolded protein response (UPR mt ) and PINK1/Parkin mitophagy. However, beyond the up-regulation of chaperones and proteases, we have a limited understanding of how the UPR mt remodels and restores damaged mitochondrial proteomes. Here, we have developed a functional proteomics framework, termed MitoPQ (Mitochondrial Proteostasis Quantification), to dissect the UPR mt ’s role in maintaining proteostasis during stress. We find essential roles for the UPR mt in both protecting and repairing proteostasis, with oxidative phosphorylation metabolism being a central target of the UPR mt . Transcriptome analyses together with MitoPQ reveal that UPR mt transcription factors drive independent signaling arms that act in concert to maintain proteostasis. Unidirectional interplay between the UPR mt and PINK1/Parkin mitophagy was found to promote oxidative phosphorylation recovery when the UPR mt failed. Collectively, this study defines the network of proteostasis mediated by the UPR mt and highlights the value of functional proteomics in decoding stressed proteomes.
- 22 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (38) , eadh8228
Open AccessTemporal landscape of mitochondrial proteostasis governed by the UPR mt
Breakdown of mitochondrial proteostasis activates quality control pathways including the mitochondrial unfolded protein response (UPR mt ) and PINK1/Parkin mitophagy. However, beyond the up-regulation of chaperones and proteases, we have a limited understanding of how the UPR mt remodels and restores damaged mitochondrial proteomes. Here, we have developed a functional proteomics framework, termed MitoPQ (Mitochondrial Proteostasis Quantification), to dissect the UPR mt ’s role in maintaining proteostasis during stress. We find essential roles for the UPR mt in both protecting and repairing proteostasis, with oxidative phosphorylation metabolism being a central target of the UPR mt . Transcriptome analyses together with MitoPQ reveal that UPR mt transcription factors drive independent signaling arms that act in concert to maintain proteostasis. Unidirectional interplay between the UPR mt and PINK1/Parkin mitophagy was found to promote oxidative phosphorylation recovery when the UPR mt failed. Collectively, this study defines the network of proteostasis mediated by the UPR mt and highlights the value of functional proteomics in decoding stressed proteomes.
- Open Access
- 15 August 2023
- Published by Springer Nature
Calculating mitochondrial protein solubility v1
Protocol for generating solubility calculations for mitochondrial proteins from starting 'soluble' and 'insoluble' fraction mass spectrometry data, using MaxQuant and Perseus software pipelines.
- 15 August 2023
- Published by Springer Nature
Open AccessCalculating mitochondrial protein solubility v1
Protocol for generating solubility calculations for mitochondrial proteins from starting 'soluble' and 'insoluble' fraction mass spectrometry data, using MaxQuant and Perseus software pipelines.
- Open Access
- 9 August 2023
- Published by Springer Nature
Induction of starvation stress v1
Induction of starvation stress using EBSS in HeLa cells
- 9 August 2023
- Published by Springer Nature
Open AccessInduction of starvation stress v1
Induction of starvation stress using EBSS in HeLa cells
- Open Access
- 9 August 2023
- Published by Springer Nature
Mitochondrial isolation from HeLa cells v1
Mitochondrial isolation and quantification from HeLa cells.
- 9 August 2023
- Published by Springer Nature
Open AccessMitochondrial isolation from HeLa cells v1
Mitochondrial isolation and quantification from HeLa cells.
- Open Access
- 9 August 2023
- Published by Springer Nature
Reverse-phase high pH fractionation (using Thermo Fisher, Cat# 84868) v1
This protocol uses the Pierce™ High pH Reversed-Phase Peptide Fractionation Kit (Thermo Fisher, Cat# 84868)
- 9 August 2023
- Published by Springer Nature
Open AccessReverse-phase high pH fractionation (using Thermo Fisher, Cat# 84868) v1
This protocol uses the Pierce™ High pH Reversed-Phase Peptide Fractionation Kit (Thermo Fisher, Cat# 84868)
- Open Access
- 9 August 2023
- Published by Springer Nature
Preparing mitochondrial samples for immunoblot analysis v1
Protocol for preparation of mitochondrial samples for immunoblot analysis.
- 9 August 2023
- Published by Springer Nature
Open AccessPreparing mitochondrial samples for immunoblot analysis v1
Protocol for preparation of mitochondrial samples for immunoblot analysis.
- Open Access
- 9 August 2023
- Published by Springer Nature
Immunofluorescence Assay (IFA) v1
Protocol for performing an immunofluorescence assay with fixed HeLa cells.
- 9 August 2023
- Published by Springer Nature
Open AccessImmunofluorescence Assay (IFA) v1
Protocol for performing an immunofluorescence assay with fixed HeLa cells.